New pill targets hard-to-treat cancer mutation in early human trial

NCT ID NCT06667544

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study tests an experimental drug called RNK08954 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. About 152 adults who have already tried standard treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12D MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Chest Hospital

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.